HS-10516

· Jiangsu Hansoh Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HS-10516, covering 2024-08-14 to 2025-08-01. Get the full timeline:

Most recent: Clinical Trial Update: Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma [Phase 1, Phase 2]